CalcMyPeptide
Healing & RecoveryAlso known as: Tα1, Zadaxin, Thymalfasin

Thymosin Alpha-1

Thymosin Alpha-1 (Tα1) is a 28-amino-acid thymic peptide, globally recognized as one of the most powerful immunomodulators in existence, approved as an orphan drug (Zadaxin) in 35+ countries. Rather than simply suppressing or boosting immunity blindly, Tα1 is an intelligent "immune orchestrator." It is clinically deployed against devastating pathologies including Hepatitis B/C, Lyme disease, aggressive fungal infections, and profound immunosenescence. It forcefully reboots an exhausted immune system, shifting it from a chaotic inflammatory state to a lethal, highly targeted cellular defense posture.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Moderate6 peer-reviewed citations

Quick Stats

Half-LifeApproximately 2 hours
Dose Range1.6-3.2 mg twice weekly
Frequency2× weekly
Vial Sizes5 mg, 10 mg, 20 mg
BioavailabilityHigh when injected subcutaneously (rapid absorption, peak at ~2 hours)
Year Developed1972

Scientific Data

Molecular Formula
C129H215N33O55
Molecular Weight
3108.32 g/mol
CAS Number
PubChem ID

Patient Suitability

Best For

  • Chronic Hepatitis B or C Support
    Helps clear viral loads and normalize liver enzymes
  • Cancer Treatment Support
    May help maintain immune function alongside chemotherapy
  • Age-Related Immune Decline
    Keeps immune defenses more youthful and responsive
  • Severe Infection Recovery
    Shown promise for reducing mortality by restoring immune balance (e.g. sepsis)

Avoid If

  • Organ transplant patients taking immunosuppressants
  • Active autoimmune disease flare
  • Pregnancy or breastfeeding
  • Severe allergic reaction history
  • Under 18 without medical supervision

! Use With Caution If

  • Autoimmune condition (even in remission)
  • Medications affecting immune function
  • History of allergic reactions to peptides
  • Cancer immunotherapy
  • Kidney or liver disease

Mechanism of Action

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age. Thymosin Alpha-1 (Tα1) plays a central role in adaptive immunity by orchestrating T-cell maturation, differentiation, and activation. Tα1 activates toll-like receptors (TLR2, TLR9), enhances dendritic cell presentation, stimulates natural killer (NK) cells, and promotes T-helper cell differentiation.

FDA-designated as an orphan drug (Zadaxin) and approved in 35+ countries for hepatitis B and C treatment. Clinical studies also demonstrate efficacy as an immune adjuvant in cancer therapy and vaccine enhancement. Uniquely, it has the ability to boost immunity while preventing harmful overreaction through IDO pathway activation.

Source: PMID: 17316418

Background & History

Thymosin Alpha-1 (Tα1, Thymalfasin) is a 28-amino-acid peptide isolated from the thymus gland in 1972 by Allan Goldstein at Albert Einstein College of Medicine — the same researcher who earlier discovered Thymosin Beta-4. It is one of the most studied immunomodulatory peptides with FDA orphan drug status for multiple conditions and commercial approval in 35+ countries (Zadaxin, SciClone Pharmaceuticals) for hepatitis B, hepatitis C, and various immunocompromised states. It is the flagship "thymic peptide" proven to restore immune competence.

Research Use Cases

  • Hepatitis B and C treatment (approved in 35+ countries as Zadaxin)
  • Immunocompromised states: chemotherapy, HIV, organ transplant recovery
  • Sepsis and critical illness immune support
  • Cancer immunotherapy adjunct — enhancing NK and T-cell activity
  • Long COVID immune restoration

Dosing Protocols

🌱

Starting Dose

Dose
1.6 mg
Frequency
Twice weekly
Duration
4 weeks
Note: This is the standard clinical dose used in most research trials. Start here to assess your tolerance and response.

Standard Protocol

Dose
1.6 mg
Frequency
Twice weekly
Duration
8-12 weeks
Note: Most common protocol used in clinical trials. Inject on consistent days (like Monday/Thursday).

Advanced Protocol

Dose
1.6 mg daily for 7 days, then twice weekly
Frequency
Daily initially, then twice weekly
Duration
12+ weeks
Note: Used in some severe infection and critical care protocols under medical supervision.

When to Increase:

  • Tolerated the starting protocol well for 4+ weeks
  • Healthcare provider recommends intensification
  • Blood work shows continued immune markers that could benefit from support

When to Decrease:

  • Persistent flu-like symptoms beyond the first week
  • Injection site reactions don't improve with site rotation
  • Develop signs of immune overstimulation
  • Autoimmune symptoms emerge or worsen

Body-Weight Dosing Reference

Estimated doses extrapolated from the published research range of 16003200 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.

WeightLowTargetHigh
120 lb(54 kg)1234 mcg1851 mcg2469 mcg
140 lb(63 kg)1440 mcg2160 mcg2880 mcg
160 lb(73 kg)1669 mcg2503 mcg3337 mcg
180 lb(82 kg)1874 mcg2811 mcg3749 mcg
200 lb(91 kg)2080 mcg3120 mcg4160 mcg
220 lb(100 kg)2286 mcg3429 mcg4571 mcg
250 lb(113 kg)2583 mcg3874 mcg5166 mcg

💉 For exact syringe units based on your vial concentration, use the Thymosin Alpha-1 Reconstitution Calculator →

Administration & Storage

Preparation

Route
Subcutaneous injection (just under the skin)
Best Injection Sites
Abdominal area (2 inches away from navel), Front or outer thigh, Back of upper arm
Required Supplies
  • Bacteriostatic water (BAC water)
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs

Storage Guidelines

Before Reconstitution
Keep lyophilized powder refrigerated at 36-46°F (2-8°C) for up to 2 years. Protect from light.
After Reconstitution
Refrigerate at 36-46°F (2-8°C) immediately. Never freeze reconstituted solution. Use within 14-21 days.
! Signs of Degradation
Cloudiness or haziness • Visible particles or floaters • Color change • Unusual smell

Reconstitution Example

Vial
5 mg
Water
1 mL
Concentration
5 mg/mL
Per Unit (100u syringe)
50 mcg
Dose of 1600 mcg = 32 units on a 100-unit insulin syringe

Safety & Considerations

Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it does not accumulate in your system. It has been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Regulatory & Legal Status

FDA Status (US)
Research Only

Approved in 37+ countries (including Italy, China) as Zadaxin®; not FDA-approved in the US

WADA Status (2026)
Prohibited (S4)

Competitive athletes subject to anti-doping controls should not use Thymosin Alpha-1.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Interactions & Contraindications

Very favorable safety profile — used in critically ill patients without significant drug interactions. May potentiate effects of checkpoint inhibitors (immunotherapy drugs); monitor with oncology team. Do not combine with immunosuppressants (cyclosporine, tacrolimus) — opposing mechanisms.

Synergies & Common Stacks

BPC-157 handles tissue repair; Thymosin Alpha-1 restores immune competence. Together support comprehensive recovery from surgery, illness, or infection.

LL-37 provides direct antimicrobial activity while Tα1 amplifies systemic adaptive immune response. Combined immune support across innate and adaptive arms.

Thymosin Alpha-1 vs. TB-500

AttributeThymosin Alpha-1TB-500
MechanismImmune modulation + thymic activationActin polymerization + cell migration
Primary UseImmune support, infection, cancer adjuvantPhysical tissue healing, injury recovery
Evidence QualityHuman trials (37+ country approval)Primarily preclinical
WADA StatusProhibited (S4)Prohibited (S0)
Dose Frequency900 mcg – 1.6 mg 2× weekly2–5 mg 2× weekly

Verdict: Thymosin Alpha-1 targets immunity; TB-500 targets tissue healing. These peptides address completely different goals with minimal overlap — they are not competing options but complementary tools.

What to Expect

Weeks 1-2

You Might Notice:
  • Mild injection site reactions
  • Possible flu-like symptoms
  • Slightly more fatigue
  • Nothing dramatic
Next Steps:
  • Side effects typically improve
  • Continue twice-weekly schedule consistently

Weeks 3-4

You Might Notice:
  • Injection tolerance improves significantly
  • Feeling more resilient to minor bugs
  • Energy levels stabilize
  • Viral markers may start improving
Next Steps:
  • Continue consistent dosing
  • Clinical benefits become measurable

Weeks 5-6+

You Might Notice:
  • Established benefits maintained
  • Fewer or shorter illnesses
  • Improved lab markers
  • Overall sense of immune competence
Next Steps:
  • Discuss continuation with provider
  • Some protocols continue long-term; others take breaks

Dosing Quick Reference

Thymosin Alpha-1— Dosing Guide
Dose Range
1.6-3.2 mg twice weekly
Half-Life
~2 hours
Frequency
2× weekly
Route
Subcutaneous
5 mg vial10 mg vial20 mg vial
💧 1 mL BAC water📐 5 mg/mL concentration💉 50 mcg/unit (100u syringe)
Healing & Recoverycalcmypeptide.com

Frequently Asked Questions

Is Thymosin Alpha-1 FDA-approved?
It has FDA orphan drug designation (Zadaxin) and is fully approved in 35+ countries for hepatitis B/C treatment. It is also widely used as an immune adjuvant in oncology settings worldwide.
How does Thymosin Alpha-1 differ from Thymosin Beta-4 (TB-500)?
Different peptides with different functions. Alpha-1 is an immune modulator (T-cell/NK cell activation). Beta-4 (TB-500) is a tissue repair peptide (actin regulation, wound healing). They target completely different systems.

References

  1. Garaci E, Pica F, Matteucci C "Historical review on thymosin α1 in oncology".” Expert Opin Biol Ther (2015). PMID: 26096345
  2. Romani L, Moretti S, Fallarino F "Jack of all trades: thymosin α1 and its pleiotropy".” Ann N Y Acad Sci (2012). PMID: 23045964
  3. Chen JF, Chen SR, Lei ZY "Safety and efficacy of Thymosin α1 in the treatment of hepatitis B...".” Front Immunol (2022). PMID: 35616850
  4. Ancell CD, Phipps J, Young L "Thymosin alpha-1 (Review)".” Am J Health Syst Pharm (2001). PMID: 11381492

📚 Related Articles

Recommended Source10% OFF

Get Thymosin Alpha-1 from our recommended source — independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.

Affiliate link · Full review